New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE ...

RALEIGH, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences ...

The UAB Office of Service Learning and Undergraduate Research connects students, faculty, and community nonprofit partners to enrich student academic learning, promote civic engagement, and to ...

HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase ...

WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

The retrospective analysis of nearly 15,000 general anesthesia cases of adults (18 years and older) at the University of Michigan demonstrated End-tidal Control’s association with reduced anesthetic ...

Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with ...